Meveol Results

 

 

A few results

In Vitro trials application on main strains (Pseudomonas aeruginosa, Burkholderia cepacia, Methycillin Resistant Staphylococcus Aureus).
 
In Vivo trials application

 

 

Pseudomonas aeruginosa (Mucoid)

 

 Evolution of the bacterial concentration (P. aeruginosa mucoïd) with time
Strain isolated from Cystic
Fibrosis patients
 
 Active compound at To* only
 

 

 

 

Methycillin Resistant Staphylococcus Aureus (MRSA)

 

Evolution of the bacterial concentration (S. aureus) with time
ATCC 43300
 
Active compound at To* only
 

 

 

 

 

Burkholderia cepacia

 

Evolution of bacterial concentration (B. cepacia) with time
ATCC BAA-245
 
Active compound at To* only

 

 

 

 

In Vivo Efficacy

 

Mice lung 72h after contamination by 10! CFU mucoid Pseudomonas aeruginosa

 

 

Development of a treatment to fight against Cystic Fibrosis
The regulatory preclinical study was co-financed by E.U. Europe is moving in Rhone Alpes with the European Regional Development Fund.